AIDS CLINICAL TRIALS

艾滋病临床试验

基本信息

  • 批准号:
    2063177
  • 负责人:
  • 金额:
    $ 144.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1987
  • 资助国家:
    美国
  • 起止时间:
    1987-09-30 至 1995-12-31
  • 项目状态:
    已结题

项目摘要

For the 1991 ACTG recompetition, the independent ACTUs at Cornell University Medica College (CUMC) and Memorial Sloan-Kettering Cancer Center (MSKCC) have elected to merge as one Main ACTU and add two new Subunits, St. Clare's Hospital in Manhattan and North Shore University Hospital on Long Island. MSKCC is also applying for Virology and Pharmacology Core Laboratories. The merger of the CUMC and MSKCC ACTUs will provide the key opportunities to (a) streamline and consolidate shared ACTU activities, (b) increase cost efficiency while maintaining enrollment, and (c) rationally focus and direct high priority trials at one site which has either recognized clinical expertise or an optimal dedicated clinical facility. The addition of St. Clare's (the most active HIV Unit on the East Coast) and North Shore as Subunits will enhance accrual of women, minorities, IVDUs, and prisoners, extend the ACTG network to underserved areas of New York City (Queens) and Long Island, and provide the ACTG with additional investigators expert in HIV-related disease. The CUMC and MSKCC ACTUs have made clear scientific contributions to the ACTG, and have demonstrated high-level accomplishments in phase I, II, and III protocols in three ACTG priority areas: Primary HIV Infection, Opportunistic Infections (OI), and Oncology in OI trials enrollment, CUMC- MSKCC together ranks first in New York City and seventh nationally, and in Oncology trials enrollment ranks first in New York City and second nationally. Maintaining this high level of participation in OI and Oncology studies will be the primary objective of the new CUMC-MSKCC ACTU and its Subunits. In addition to the large endogenous patient populations already at the Main CUMC-MSKCC ACTU sites and the two Subunits (both are New York State Designated AIDS Care Units), more than 40 separate linkages will also be used as sources of trials patients with clear emphasis on recruitment of under-represented groups. Other particularly important components of the new CUMC-MSKCC ACTU include a new large (dedicated) outpatient unit, a supportive GCRC, investigators skilled in OI and Oncology trials, an active Community Advisory Board, and nursing, administrative, data management, and pharmacy staffs thoroughly experienced in ACTG clinical trials work. Together, CUMC-MSKCC with its Subunits provides a unique ACTU for conducting high priority ACTG studies.
对于1991年的ACTG再竞赛,康奈尔大学的独立actu

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HENRY W. MURRAY其他文献

HENRY W. MURRAY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HENRY W. MURRAY', 18)}}的其他基金

Immunochemotherapy in Visceral Leishmaniasis
内脏利什曼病的免疫化疗
  • 批准号:
    8417753
  • 财政年份:
    2010
  • 资助金额:
    $ 144.79万
  • 项目类别:
Immunochemotherapy in Visceral Leishmaniasis
内脏利什曼病的免疫化疗
  • 批准号:
    8210939
  • 财政年份:
    2010
  • 资助金额:
    $ 144.79万
  • 项目类别:
Immunochemotherapy in Visceral Leishmaniasis
内脏利什曼病的免疫化疗
  • 批准号:
    7883961
  • 财政年份:
    2010
  • 资助金额:
    $ 144.79万
  • 项目类别:
Immunochemotherapy in Visceral Leishmaniasis
内脏利什曼病的免疫化疗
  • 批准号:
    8602801
  • 财政年份:
    2010
  • 资助金额:
    $ 144.79万
  • 项目类别:
Immunochemotherapy in Visceral Leishmaniasis
内脏利什曼病的免疫化疗
  • 批准号:
    8021842
  • 财政年份:
    2010
  • 资助金额:
    $ 144.79万
  • 项目类别:
Immunochemotherapy in Visceral Leishmaniasis
内脏利什曼病的免疫化疗
  • 批准号:
    7846306
  • 财政年份:
    2009
  • 资助金额:
    $ 144.79万
  • 项目类别:
NEW TREATMENTS FOR AIDS AND AIDS-RELATED INFECTIONS
艾滋病和艾滋病相关感染的新疗法
  • 批准号:
    3546952
  • 财政年份:
    1987
  • 资助金额:
    $ 144.79万
  • 项目类别:
NEW TREATMENTS FOR AIDS AND AIDS-RELATED INFECTIONS
艾滋病和艾滋病相关感染的新疗法
  • 批准号:
    3546955
  • 财政年份:
    1987
  • 资助金额:
    $ 144.79万
  • 项目类别:
NEW TREATMENTS FOR AIDS AND AIDS-RELATED INFECTIONS
艾滋病和艾滋病相关感染的新疗法
  • 批准号:
    3546957
  • 财政年份:
    1987
  • 资助金额:
    $ 144.79万
  • 项目类别:
ADULT AIDS CLINICAL TRIALS UNIT
成人艾滋病临床试验单位
  • 批准号:
    3546953
  • 财政年份:
    1987
  • 资助金额:
    $ 144.79万
  • 项目类别:

相似海外基金

Basic and applied study on AIDS-therapy using hybrid liposomes
混合脂质体治疗艾滋病的基础与应用研究
  • 批准号:
    24656509
  • 财政年份:
    2012
  • 资助金额:
    $ 144.79万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
SIV MODEL FOR MULTI DRUG RESISTANCE TO AIDS THERAPY
艾滋病治疗多重耐药性的 SIV 模型
  • 批准号:
    6940442
  • 财政年份:
    2003
  • 资助金额:
    $ 144.79万
  • 项目类别:
RT-SHIV MODEL FOR RESISTANCE TO AIDS THERAPY
艾滋病治疗抵抗力的 RT-SHIV 模型
  • 批准号:
    6940441
  • 财政年份:
    2003
  • 资助金额:
    $ 144.79万
  • 项目类别:
Mitochondrial Toxicity of Antiviral Nucleosides in AIDS Therapy
艾滋病治疗中抗病毒核苷的线粒体毒性
  • 批准号:
    7421121
  • 财政年份:
    2002
  • 资助金额:
    $ 144.79万
  • 项目类别:
Targeted Manipulation of Stem Cells for AIDS Therapy
干细胞的靶向操作用于艾滋病治疗
  • 批准号:
    7479315
  • 财政年份:
    2001
  • 资助金额:
    $ 144.79万
  • 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
  • 批准号:
    6312501
  • 财政年份:
    2001
  • 资助金额:
    $ 144.79万
  • 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
  • 批准号:
    6499098
  • 财政年份:
    2001
  • 资助金额:
    $ 144.79万
  • 项目类别:
Targeted Manipulation of Stem Cells for AIDS Therapy
干细胞的靶向操作用于艾滋病治疗
  • 批准号:
    7666728
  • 财政年份:
    2001
  • 资助金额:
    $ 144.79万
  • 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
  • 批准号:
    6708893
  • 财政年份:
    2001
  • 资助金额:
    $ 144.79万
  • 项目类别:
TARGETED MANIPULATION OF STEM CELLS FOR AIDS THERAPY
干细胞的靶向操作用于艾滋病治疗
  • 批准号:
    6849724
  • 财政年份:
    2001
  • 资助金额:
    $ 144.79万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了